CN Patent
CN105017227B — N‑(1h‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物
Assigned to Sichuan Baili Pharmaceutical Co Ltd · Expires 2018-03-09 · 8y expired
What this patent protects
本发明记载了N‑(1H‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物。本发明提供了式I化合物或其在药学上可接受的盐。还提供了制备式I化合物的方法,和式I化合物作为药物和在癌症治疗中的用途 。
USPTO Abstract
本发明记载了N‑(1H‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物。本发明提供了式I化合物或其在药学上可接受的盐。还提供了制备式I化合物的方法,和式I化合物作为药物和在癌症治疗中的用途 。
Drugs covered by this patent
- Balversa (ERDAFITINIB) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.